Brain Regeneration Technology rose by two to three points, Intuitive Surgical edged up slightly; the medical device and small-cap biotech sectors showed some independent momentum. Pfizer was basically flat, while Hengrui Medicine and Kangfang Biotech both fell by two to three points. The innovative drug sector as a whole was relatively weak😔

On days when the broader market is volatile, the pharmaceutical sector is also stratified: surgical robots and small-cap stocks with clinical catalysts each have their own stories, while traditional pharma companies and Hong Kong-listed innovative drug stocks are still waiting for the outcome of medical insurance negotiations and data releases. Without catalysts, they can only drift along with the broader market.